Originally published by our sister publication, Gastroenterology Endoscopy News
In late July, GlaxoSmithKline announced that the FDA agreed to expand the product label for Shingrix, the company’s recombinant vaccine against herpes zoster to include immunocompromised people over age 18 years. The new indication has significant implications for patients with inflammatory bowel disease, for whom herpes zoster is a significant risk as a result of both their condition and the use of